×
4D Pharma Net Cash Flow 2019-2021 | LBPS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
4D Pharma net cash flow from 2019 to 2021. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
4D Pharma Net Cash Flow 2019-2021 | LBPS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
4D Pharma net cash flow from 2019 to 2021. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$76.5B
Zoetis (ZTS)
$69.3B
Takeda Pharmaceutical (TAK)
$47.9B
Daiichi Sankyo, - (DSNKY)
$42.7B
BeOne Medicines - (ONC)
$27.6B
Sandoz Group AG (SDZNY)
$24.9B
Summit Therapeutics (SMMT)
$18.9B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.2B
United Therapeutics (UTHR)
$13.4B
Neurocrine Biosciences (NBIX)
$13.4B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.3B
Stevanato Group S.p.A (STVN)
$7.8B
Corcept Therapeutics (CORT)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.1B
Ionis Pharmaceuticals (IONS)
$6.8B
Grifols, S.A (GRFS)
$6.7B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.3B
Soleno Therapeutics (SLNO)
$4.2B
Crinetics Pharmaceuticals (CRNX)
$3.1B
Hypermarcas (HYPMY)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2B
BioCryst Pharmaceuticals (BCRX)
$1.9B
Ocular Therapeutix (OCUL)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B